Literature DB >> 163846

Growth hormone release after synthetic 1-24 ACTH: effects of estrogen and sex.

M R Stjernholm, R N Alsever, P Beck.   

Abstract

Recent reports have demonstrated that growth hormone (GH) is inconsistently released after intravenous administration of synthetic 1-24 ACTH. This study was designed to evaluate the role of estrogens in mediating this response. 250 mug of synthetic 1-24 ACTH were administered to 8 men in 12 studies and 6 women in 11 studies. None of the men exhibited a rise in GH after 1-24 ACTH, while the women exhibited a significant increase. Pretreatment of 5 of these men with 100 mug of ethinyl estradiol daily for 3 days did not alter GH response from the initial studies. Pretreatment with 10 mg of diethylstilbesterol daily for 3 days, however, resulted in a rise in GH which was similar to the female group. It is concluded that the variable GH responses to synthetic 1-24 ACTH may be in part due to prevailing concentrations of sex steroids and their effect on the hypothalamic-pituitary GH release mechanism.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 163846     DOI: 10.1210/jcem-40-3-516

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

Review 1.  Potential role of type I interferons in the treatment of pituitary adenomas.

Authors:  Giovanni Vitale; Michele Caraglia; Peter M van Koetsveld; Paola Maroni; Monica Marra; Annamaria Colao; Steven W J Lamberts; Francesco Cavagnini; Leo J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-06       Impact factor: 6.514

2.  Growth hormone (GH) and GH-releasing hormone response to ACTH 1-17 at different times of day. Evidence of a circadian stage dependence.

Authors:  Y Touitou; P Garnier; A Reinberg; L Castagno; M Donnadieu; A Bogdan; Y Motohashi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  ACTH 1-17 stimulates GH pituitary secretion in humans.

Authors:  G Valenti; A Banchini; L Denti; R Polotti; G P Ceda
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.